SCHEMBL4351082

SCHEMBL4351082

Oc1ccc(NCc2cccc(C(F)(F)F)c2)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.51
TRPV1 Q8NER1 1/20 0.51
TDO2 P48775 1/20 0.49
FFAR1 O14842 1/20 0.48
FFAR4 Q5NUL3 1/20 0.48
RPS6KB1 P23443 3/20 0.47
AURKB Q96GD4 2/20 0.47
AURKA O14965 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MAOB P27338 2/20 0.46
CHEK1 O14757 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
RPS6KA5 O75582 1/20 0.46
CHEK2 O96017 1/20 0.46
ABL1 P00519 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345824 0.79 RXFP1 (0.53) RXFP1TRPV1TDO2FFAR1FFAR4
SCHEMBL11512059 0.78 MEN1 (0.62) IDO1MEN1CYP1A2CYP3A4GAA
SCHEMBL10875877 0.78 RXFP1 (0.52) RXFP1TRPV1TDO2FFAR1FFAR4
SCHEMBL4348974 0.78 RXFP1 (0.49) RXFP1TDO2FFAR1FFAR4RPS6KB1
SCHEMBL4348993 0.78 MAPT (0.46) RPS6KB1AURKAMAOBCLK4IDO1
SCHEMBL4351131 0.77 RXFP1 (0.54) RXFP1TRPV1TDO2FFAR1FFAR4
SCHEMBL4348617 0.74 MEN1 (0.53) RXFP1TDO2FFAR1FFAR4RPS6KB1
SCHEMBL5534504 0.74 RXFP1 (0.56) RXFP1TDO2FFAR1FFAR4RPS6KB1
SCHEMBL4341276 0.73 FFAR1 (0.56) RXFP1FFAR1FFAR4RPS6KB1AURKB
SCHEMBL4342011 0.73 KDM4E (0.52) FFAR1FFAR4MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 RXFP1 1012/4885TRPV1 2328/4885TDO2 1171/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 RXFP1 1098/4885TRPV1 2320/4885TDO2 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.